115.75 0.00 (0.00%)
After hours: 4:32PM EST
|Bid||112.09 x 900|
|Ask||115.78 x 800|
|Day's Range||115.60 - 116.75|
|52 Week Range||93.88 - 117.10|
|Beta (5Y Monthly)||0.83|
|PE Ratio (TTM)||51.44|
|Earnings Date||Jan 23, 2020|
|Forward Dividend & Yield||0.84 (0.73%)|
|Ex-Dividend Date||Dec 11, 2019|
|1y Target Est||125.56|
Hill-Rom (HRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Boston Scientific's (BSX) recent takeovers of BTG, NxThera, Claret Medical, VENITI and Augmenix make us optimistic about their positive synergies to be added to the company portfolio.
Although corporate earnings growth were negative year over year in the first three quarters, results were far better than initially anticipated.
Globus Medical (GMED) delivers solid spine sales globally. Enabling Technologies too rides high on the rising uptake of ExcelsiusGPS platform.
The Zacks Analyst Blog Highlights: SL Green Realty, American Express, Hill-Rom, Invesco and LPL Financial
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]
Hologic (HOLX) expects to generate robust Surgical and Diagnostics revenues in Q1, though softness in the divested Medical Aesthetics business remains a concern.
Medtronic's (MDT) Percept PC neurostimulator DBS system, with BrainSense technology, receives the CE Mark, thus clearing the way for the treatment of various neurologic disorders in the EU.
Hill-Rom (HRC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...
Hill-Rom (HRC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Teleflex (TFX) receives FDA clearance for expanded indication for the utilization of the UroLift System for treating larger prostrates in men.
Medtronic (MDT) acquires Stimgenics to integrate DTM therapy in its pain therapies segment. It will also present trial results favoring the therapy at the upcoming NANS meeting.
Abbott's (ABT) less invasive approach for heart surgery for its heart pump gets the FDA clearance, thus paving the way for avoiding open heart surgeries.